Preferred Label : benzimidazoles;

MeSH definition : Compounds with a BENZENE fused to IMIDAZOLES.;

Codes EINECS : 200-081-4;

Is substance : O;

medicament (CISMeF) : O;

Details


Main resources

You can consult :

Compounds with a BENZENE fused to IMIDAZOLES.

http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64454186
2021
false
false
false
France
French
bilastine
summary of product characteristics
package leaflet
bilastine
benzimidazoles
piperidines

---
https://www.has-sante.fr/jcms/p_3280978/fr/maviret-vhc-pediatrique
2021
false
false
false
France
glecaprevir and pibrentasvir
administration, oral
insurance, health, reimbursement
treatment outcome
child
hepatitis C, chronic
antiviral agents
evaluation of the transparency committee
glecaprevir
pibrentasvir
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines
quinoxalines
sulfonamides

---
https://ansm.sante.fr/tableau-atu-rtu/selumetinib-10-mg-gelules
2021
false
false
false
France
French
administration, oral
selumetinib
selumetinib
summary of product characteristics
package leaflet
guidelines for drug use
child
neurofibromatosis 1
neurofibroma, plexiform
Mitogen-Activated Protein Kinase Kinase Inhibitor
MAPK-ERK kinases
protein kinase inhibitors
Product containing precisely selumetinib 25 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely selumetinib 10 milligram/1 each conventional release oral capsule (clinical drug)
Tyrosine Kinase Inhibitors
AZD 6244
Mitogen-Activated protein kinase kinases
benzimidazoles

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61897454
2021
false
false
false
France
French
administration, oral
summary of product characteristics
package leaflet
telmisartan, hydrochlorothiazide drug combination
antihypertensive agents
telmisartan and diuretics
benzimidazoles
benzoates
hydrochlorothiazide
drug combinations
Telmisartan

---
https://www.has-sante.fr/jcms/p_3237418/fr/verzenios-abemaciclib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
abemaciclib
antineoplastic combined chemotherapy protocols
postmenopause
breast neoplasms
antineoplastic agents
administration, oral
neoplasm metastasis
Abemaciclib/Fulvestrant Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
evaluation of the transparency committee
abemaciclib
aminopyridines
benzimidazoles

---
https://www.has-sante.fr/jcms/p_3152635/fr/harvoni
2020
false
false
false
France
Sofosbuvir
treatment outcome
ledipasvir
ledipasvir, sofosbuvir drug combination
adult
adolescent
antiviral agents
drug combinations
hepatitis C, chronic
evaluation of the transparency committee
Harvoni
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/daurismo-5332.html
2020
false
false
false
Canada
French
drug evaluation
Glasdegib
Glasdegib Maleate
glasdegib
glasdegib
benzimidazoles
phenylurea compounds

---
https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Glasdegib
Glasdegib
benzimidazoles
benzimidazoles
phenylurea compounds
phenylurea compounds
glasdegib
antineoplastic agents
antineoplastic agents
adult
aged
antineoplastic combined chemotherapy protocols
cytarabine
leukemia, myeloid, acute
orphan drug production
administration, oral
SMO protein, human
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Glasdegib Maleate
Glasdegib Maleate
glasdegib
glasdegib
Smoothened Receptor
receptors, g-protein-coupled

---
https://www.has-sante.fr/jcms/p_3224398/fr/maviret
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
glecaprevir and pibrentasvir
Glecaprevir/Pibrentasvir
glecaprevir
pibrentasvir
antiviral agents
insurance, health, reimbursement
Duration of treatment (qualifier value)
hepatitis C, chronic
glecaprevir
benzimidazoles
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
drug combinations
pyrrolidines

---
https://www.has-sante.fr/jcms/p_3224404/fr/harvoni
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
ledipasvir, sofosbuvir drug combination
Product containing only ledipasvir and sofosbuvir in oral dose form (medicinal product form)
antiviral agents
hepatitis C, chronic
child
adolescent
adult
sofosbuvir and ledipasvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
https://www.has-sante.fr/jcms/p_3114485/fr/maviret
2019
false
false
false
France
glecaprevir and pibrentasvir
adult
adolescent
hepatitis C, chronic
glecaprevir
pibrentasvir
antiviral agents
insurance, health, reimbursement
treatment outcome
administration, oral
evaluation of the transparency committee
glecaprevir
quinoxalines
sulfonamides
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines

---
https://www.has-sante.fr/jcms/p_3114479/fr/maviret
2019
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
antiviral agents
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
glecaprevir
pibrentasvir
administration, oral
glecaprevir and pibrentasvir
hepatitis C, chronic
adult
adolescent
renal insufficiency, chronic
Duration of treatment (qualifier value)
glecaprevir
quinoxalines
sulfonamides
benzimidazoles
glecaprevir and pibrentasvir
drug combinations
pyrrolidines

---
https://www.has-sante.fr/portail/jcms/c_2892921/fr/verzenios
2019
false
false
false
France
French
treatment outcome
abemaciclib
antineoplastic combined chemotherapy protocols
postmenopause
breast neoplasms
neoplasm metastasis
neoplasm recurrence, local
administration, oral
antineoplastic agents
antineoplastic agents
Hormone receptor positive malignant neoplasm of breast (disorder)
insurance, health, reimbursement
evaluation of the transparency committee
abemaciclib
abemaciclib
aminopyridines
benzimidazoles
aminopyridines
benzimidazoles

---
https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
binimetinib
binimetinib
drug approval
europe
treatment outcome
melanoma
antineoplastic combined chemotherapy protocols
encorafenib
BRAF V600 Mutation
melanoma
mutation
proto-oncogene proteins b-raf
administration, oral
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
MAP kinase kinase 1
MAP kinase kinase 2
Progression-Free survival
survival analysis
drug evaluation, preclinical
Binimetinib/Encorafenib Regimen
Tyrosine Kinase Inhibitors
binimetinib
binimetinib
benzimidazoles
binimetinib
disease-free survival
benzimidazoles
carbamates
sulfonamides

---
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni-sofosbuvir/ledipasvir-antiviral-a-action-directe
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni
2018
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
guidelines for drug use
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
adolescent
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
Verzenios abemaciclib
https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
breast neoplasms
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
abemaciclib
product surveillance, postmarketing
food-drug interactions
drug interactions
pregnancy
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
survival analysis
drug evaluation, preclinical
Abemaciclib/Fulvestrant Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
abemaciclib
abemaciclib
aminopyridines
benzimidazoles
aminopyridines
benzimidazoles

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00392
2018
false
false
false
Canada
French
English
drug information
flibanserin
drug approval
canada
administration, oral
hypoactive sexual desire disorder
female
serotonin 5-HT1 receptor antagonists
serotonin 5-HT1 receptor antagonists
serotonin 5-HT2 receptor antagonists
serotonin 5-HT2 receptor antagonists
drug evaluation
product surveillance, postmarketing
flibanserin
benzimidazoles
sexual dysfunctions, psychological
benzimidazoles
benzimidazoles

---
https://www.has-sante.fr/portail/jcms/c_2777965/fr/micardisplus
2017
false
false
false
France
French
evaluation of the transparency committee
Micardis-HCT
telmisartan, hydrochlorothiazide drug combination
drug combinations
treatment outcome
insurance, health, reimbursement
hypertension
telmisartan and diuretics
hydrochlorothiazide
benzimidazoles
benzoates
Telmisartan

---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds

---
Maviret - glecaprevir / pibrentasvir
https://www.ema.europa.eu/medicines/human/EPAR/Maviret
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
treatment outcome
product surveillance, postmarketing
drug combinations
antiviral agents
antiviral agents
tablets
administration, oral
hepatitis C, chronic
adult
drug interactions
pregnancy
breast feeding
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
Substance with Hepatitis C virus protein NS5A inhibitor mechanism of action (substance)
drug evaluation, preclinical
glecaprevir and pibrentasvir
benzimidazoles
benzimidazoles
glecaprevir
glecaprevir
pibrentasvir
pibrentasvir
glecaprevir
glecaprevir
quinoxalines
sulfonamides
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
pyrrolidines

---
http://www.has-sante.fr/portail/jcms/c_2740883/fr/mizollen
2017
false
false
false
France
French
evaluation of the transparency committee
mizolastine
mizolastine
benzimidazoles

---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil

---
http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-10-fra.php#a19
2016
false
false
false
Canada
French
azilsartan medoxomil and diuretics
drug combinations
chlorthalidone
azilsartan medoxomil
hyponatremia
pharmacovigilance note
benzimidazoles
oxadiazoles

---
http://www.has-sante.fr/portail/jcms/c_2633680/fr/antiviraux-d-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
adult
hepatitis C, chronic
drug therapy, combination
Sofosbuvir
antiviral agents
direct acting antivirals
daclatasvir
Simeprevir
ledipasvir, sofosbuvir drug combination
dasabuvir
drug combinations
ombitasvir
ritonavir
paritaprevir
fibrosis, liver
risk
has patient
hepacivirus
Infections
autoimmune diseases
hepatic fibrosis, nos
fibrosis
hepatitis C virus
human enterovirus 72
hepatitis C, chronic
business
liver cirrhosis
socialism
patients
chronic infectious disease
guideline
antiviral agents
chronic hepatitis, nos
health
case management
hepatitis c virus
hepatitis a virus
dasabuvir
ombitasvir
paritaprevir
daclatasvir
fibrosis
commerce
patients
guideline
benzimidazoles
fluorenes
uridine monophosphate
sulfonamides
uracil
uracil
anilides
carbamates
macrocyclic compounds
imidazoles

---
http://www.has-sante.fr/portail/jcms/c_2658549/fr/hytacand
http://www.has-sante.fr/portail/jcms/c_1036303/hytacand
http://www.has-sante.fr/portail/jcms/c_400717/fr/hytacand-8-mg/12-5-mg-comprime-plaquettes-thermoformees-pvc-aluminium-pvdc-de-28-comprimes-code-cip-353-911-3
2016
false
France
French
adult
diuretics
hydrochlorothiazide
tetrazoles
angiotensin II type 1 receptor blockers
benzimidazoles
biphenyl compounds
drug combinations
antihypertensive agents
candesartan cilexetil
candesartan and diuretics
administration, oral
insurance, health, reimbursement
hypertension
sodium chloride symporter inhibitors
evaluation of the transparency committee

---
https://afef.asso.fr/wp-content/uploads/2018/06/VF-INTERACTIF-RECO-VHC-AFEF-v2103.pdf
http://www.infectiologie.com/UserFiles/File/medias/Recos/2015-juin-Recommandations-AFEF-Hepatite-C.pdf
2016
false
false
true
false
France
French
hepatitis C, chronic
practice guideline
severity of illness index
hepatitis C, chronic
antiviral agents
comorbidity
genotype
daclatasvir
ledipasvir
ribavirin
treatment outcome
drug resistance, viral
pregnancy
patient education as topic
liver cirrhosis
liver transplantation
recurrence
renal insufficiency
child
adolescent
drug users
hiv infections
acute disease
Acute hepatitis C
Simeprevir
Sofosbuvir
ledipasvir
ledipasvir, sofosbuvir drug combination
daclatasvir
imidazoles
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
Summary Basis of Decision (SBD) for Blexten
Bilastine, 20 mg, tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00282
2016
false
false
false
Canada
French
English
administration, oral
bilastine
Product containing bilastine (medicinal product)
drug information
histamine h1 antagonists
rhinitis, allergic, seasonal
adolescent
adult
urticaria
chronic disease
Chronic spontaneous urticaria
drug approval
canada
bilastine
tablets
benzimidazoles
piperidines

---
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni-sofosbuvir/ledipasvir-association-fixe-dantiviraux-a-action-directe
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
adult
guidelines for drug use
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 3 (organism)
Hepatitis C virus genotype 4 (organism)
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
http://www.lecrat.eu/?s=Mizolastine
2014
false
France
French
pregnancy
benzimidazoles
histamine H1 antagonists, non-sedating
mizolastine
mizolastine
benzimidazoles
drug information

---
https://www.ema.europa.eu/medicines/human/EPAR/Harvoni
2014
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
adult
hepatitis C, chronic
administration, oral
tablets
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
NS-5b protein, hepatitis C virus
treatment outcome
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
viral nonstructural proteins
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
http://www.has-sante.fr/portail/jcms/c_1719428/fr/lojuxta-lomitapide-hypocholesterolemiant
2014
false
false
false
France
French
lomitapide
lomitapide
lomitapide
Lomitapide Mesylate
administration, oral
anticholesteremic agents
anticholesteremic agents
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
treatment outcome
adult
drug therapy, combination
rare diseases
clinical trials, phase iii as topic
insurance, health, reimbursement
guidelines for drug use
evaluation of the transparency committee
BMS201038
BMS201038
benzimidazoles
benzimidazoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Kinzalkomb
2012
United Kingdom
French
English
syndication feed
Contraindications, Procedure
hypertension
hydrochlorothiazide
angiotensin II type 1 receptor blockers
antihypertensive agents
diuretics
pregnancy
breast feeding
hydrochlorothiazide
hydrochlorothiazide
angiotensin II type 1 receptor blockers
antihypertensive agents
antihypertensive agents
diuretics
diuretics
treatment outcome
drug evaluation
drug combinations
telmisartan and diuretics
telmisartan, hydrochlorothiazide drug combination
Product containing precisely hydrochlorothiazide 12.5 milligram and telmisartan 40 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely hydrochlorothiazide 12.5 milligram and telmisartan 80 milligram/1 each conventional release oral tablet (clinical drug)
Kinzalkomb
summary of product characteristics
package leaflet
drug evaluation
Contraindications, Drug
Telmisartan
benzimidazoles
benzimidazoles
benzoates
benzoates
benzimidazoles
benzoates

---
https://www.ema.europa.eu/medicines/human/EPAR/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg
2012
false
United Kingdom
French
English
syndication feed
benzimidazoles
benzoates
hypertension
angiotensin II type 1 receptor blockers
pregnancy
breast feeding
benzimidazoles
benzimidazoles
benzoates
benzoates
angiotensin II type 1 receptor blockers
angiotensin II type 1 receptor blockers
treatment outcome
drug evaluation
telmisartan
benzimidazoles
benzoates
drug evaluation
summary of product characteristics
package leaflet
Telmisartan

---
https://www.ema.europa.eu/medicines/human/EPAR/MicardisPlus
2012
United Kingdom
French
English
syndication feed
telmisartan, hydrochlorothiazide drug combination
hypertension
benzimidazoles
benzoates
angiotensin II type 1 receptor blockers
hydrochlorothiazide
diuretics
antihypertensive agents
benzimidazoles
benzoates
angiotensin II type 1 receptor blockers
hydrochlorothiazide
diuretics
antihypertensive agents
treatment outcome
drug evaluation
drug combinations
telmisartan and diuretics
benzimidazoles
benzoates
drug evaluation
summary of product characteristics
package leaflet
Telmisartan

---
https://www.ema.europa.eu/medicines/human/EPAR/PritorPlus
2012
United Kingdom
French
English
syndication feed
telmisartan, hydrochlorothiazide drug combination
treatment outcome
drug evaluation
benzoates
benzimidazoles
hydrochlorothiazide
drug combinations
hypertension
angiotensin II type 1 receptor blockers
adult
antihypertensive agents
telmisartan and diuretics
benzimidazoles
benzoates
drug evaluation
summary of product characteristics
package leaflet
Telmisartan

---
https://www.ema.europa.eu/medicines/human/EPAR/Micardis
2012
United Kingdom
French
English
syndication feed
benzimidazoles
benzoates
hypertension
angiotensin II type 1 receptor blockers
adult
treatment outcome
drug evaluation
telmisartan
benzimidazoles
benzoates
drug evaluation
summary of product characteristics
package leaflet
Telmisartan

---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%20214
France
French
benzimidazoles
benzimidazoles
carbamates
carbamates
benzimidazoles
benzimidazoles
benzimidazoles
carbamates
carbamates
carbamates
occupational exposure
occupational diseases
reference values
carbendazim
guidelines
toxicological data sheet

---
https://www.ema.europa.eu/medicines/human/EPAR/Pritor
2012
United Kingdom
French
English
syndication feed
benzimidazoles
benzoates
angiotensin II type 1 receptor blockers
hypertension
treatment outcome
drug evaluation
telmisartan
benzimidazoles
benzoates
drug evaluation
summary of product characteristics
package leaflet
Telmisartan

---
http://www.cochrane.org/fr/CD003623
2011
United Kingdom
France
French
french abstract
meta-analysis
treatment outcome
echinococcosis, hepatic
biopsy, needle
benzimidazoles

---
http://www.lecrat.eu/?s=Cand%C3%A9sartan+-+ATACAND%C2%AE%2C+KENZEN%C2%AE
2011
France
French
teratogens
pregnancy
benzimidazoles
tetrazoles
angiotensin II type 1 receptor blockers
antihypertensive agents
candesartan
candesartan
benzimidazoles
tetrazoles
drug information

---
https://www.ema.europa.eu/medicines/human/EPAR/Emadine
2009
United Kingdom
French
English
syndication feed
Contraindications, Procedure
drug approval
treatment outcome
drug evaluation
benzimidazoles
ophthalmic solutions
adult
anti-allergic agents
child
benzimidazoles
anti-allergic agents
histamine h1 antagonists
benzimidazoles
anti-allergic agents
histamine h1 antagonists
benzimidazoles
anti-allergic agents
histamine h1 antagonists
aged
benzimidazoles
anti-allergic agents
drug interactions
pregnancy
breast feeding
benzimidazoles
anti-allergic agents
histamine h1 antagonists
conjunctivitis, allergic
benzimidazoles
histamine h1 antagonists
anti-allergic agents
drug evaluation, preclinical
benzimidazoles
anti-allergic agents
histamine h1 antagonists
drug labeling
emedastine
emedastine
benzimidazoles
administration, ophthalmic
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug

---
https://www.minerva-ebp.be/fr/article/372
2009
false
false
minerva-ebm.be
Belgium
French
benzimidazoles
tetrazoles
diabetes mellitus, type 2
diabetic retinopathy
benzimidazoles
tetrazoles
angiotensin II type 1 receptor blockers
candesartan
critical appraisal or critical reading

---
https://www.minerva-ebp.be/fr/article/460
2009
false
false
minerva-ebm.be
Belgium
French
cardiovascular risk
benzimidazoles
benzoates
angiotensin-converting enzyme inhibitors
cardiovascular diseases
risk factors
angiotensin-converting enzyme inhibitors
benzimidazoles
benzoates
critical appraisal or critical reading
Telmisartan

---
https://www.minerva-ebp.be/fr/article/480
2008
false
false
minerva-ebm.be
Belgium
French
risk
cardiovascular diseases
benzimidazoles
benzoates
angiotensin-converting enzyme inhibitors
ramipril
treatment outcome
benzimidazoles
benzoates
angiotensin-converting enzyme inhibitors
ramipril
benzimidazoles
benzoates
critical appraisal or critical reading
Telmisartan
Telmisartan

---
http://www.lecrat.eu/?s=Telmisartan+-+MICARDIS%C2%AE%2C+PRITOR%C2%AE
2007
France
French
angiotensin-converting enzyme inhibitors
pregnancy
teratogens
abnormalities, drug-induced
hypertension
benzimidazoles
benzoates
angiotensin II type 1 receptor blockers
telmisartan
benzimidazoles
benzoates
drug information
Telmisartan

---
http://www.has-sante.fr/portail/display.jsp?id=c_400699
2005
France
French
diuretics
hydrochlorothiazide
tetrazoles
angiotensin II type 1 receptor blockers
benzimidazoles
biphenyl compounds
drug combinations
antihypertensive agents
candesartan cilexetil
candesartan and diuretics
benzimidazoles
biphenyl compounds
tetrazoles
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/display.jsp?id=c_398877
2001
France
French
diuretics
hydrochlorothiazide
tablets
tetrazoles
angiotensin II type 1 receptor blockers
benzimidazoles
biphenyl compounds
drug combinations
antihypertensive agents
candesartan cilexetil
candesartan and diuretics
benzimidazoles
biphenyl compounds
tetrazoles
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/display.jsp?id=c_398964
2001
France
French
diuretics
hydrochlorothiazide
tablets
tetrazoles
angiotensin II type 1 receptor blockers
benzimidazoles
biphenyl compounds
drug combinations
antihypertensive agents
candesartan cilexetil
candesartan and diuretics
benzimidazoles
biphenyl compounds
tetrazoles
evaluation of the transparency committee

---
Nous contacter.
11/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.